Reclast is an osteoporosis drug owned by Novartis. It contains the active ingredient zoledronic acid. It was first authorized for market use on 16 April, 2007 and it's available in injectable, intravenous dosage forms. The drug holds 3 patents, one of which has already expired.
The release of Reclast generic may be possible after 05 August, 2028. This is based on the expiration of the patent US7932241*PED titled 'Pharmaceutical products comprising bisphosphonates' which expires on 2028-08-05.
Reclast, with its active ingredient zoledronic acid, is used for the treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis. It also helps increase bone mass in men with osteoporosis.
Reclast holds 3 patents, with the last one set to expire on 05 August, 2028, upon which Reclast generic may become available. Below are the details of the patent: